METiS Pharmaceuticals Named to 'China Entrepreneur' Magazine's 2024 'Top 100 Emerging Companies' List Amid Hong Kong IPO Filing

Aug 28, 2024 13:39 CST Updated 13:39

METiS TechBio

AI-Driven Drug Formulation Developer

Recently, the magazine "China Entrepreneur" officially released2024 "Emerging 100"Enterprise List: As a leading enterprise representative in the "AI + Drug Delivery" field, METiS TechBio (METiS Pharmaceuticals) has been selected as one of the 100 New Sharp Companies of the Year.

China Entrepreneur magazine, founded in 1985 and affiliated with the Economic Daily, is a mainstream business and finance magazine in China. Its "Future Stars" series of rankings has been running for 24 years, uncovering 504 innovative companies, among which are today's tech giants such as Tencent, Baidu, Xiaomi, Meituan, JD.com, and NIO.As one of the "Rising Stars" series selection events, the "Emerging 100" list aims to identify industry leaders from high-potential companies by comprehensively evaluating factors such as innovation, high growth potential, and social recognition.

The list focuses on start-up companies established within no more than 5 years, with a valuation of over 500 million RMB or at the angel round of financing or above.Through methods such as online solicitation, recommendations from investment institutions and professional groups, third-party data companies, and other public channels, with objective data such as company valuation, financing rounds, and operating income as the main basis, ultimatelyFinally selected from 13 industries and tens of thousands of companies, this year's list also includes companies such as Baichuan Intelligence and MoonShot.

AsOne of the world's leading drug delivery platforms, METiS TechBio, in the absence of open-source datasets and delivery-related algorithms, started from scratch and innovatively developed groundbreaking artificial intelligence and computational simulation algorithms for the generation and design of ionizable lipids and the design and simulation of LNP nanomaterials. Combined with world-leading high-throughput experimental techniques and animal validation platforms, they have established their own data and algorithm barriers.

Currently, METiS TechBio has independently developed three major AI+ core technology platforms:AI-Driven Nucleic Acid Delivery System Design Platform (AiLNP)、AI-Driven mRNA Sequence Design Platform (AiRNA)、AI-Driven Small Molecule Formulation Design Platform (AiTEM), and has developed a proprietary technology route for METiS TechBio that deeply integrates dry and wet experiments, thereby achieving efficient drug delivery and drug discovery.

Based on the AI drug delivery platform and integrating the rapidly advancing large models and generative AI technologies, METiS TechBio has established the world's first METiSLipidLM lipid language model and PhatGPT lipid generation model, creating a million-level lipid library and successfully breaking through international patent barriers. Meanwhile, METiS TechBio combines innovative molecular simulation technology to simulate various microscopic processes of LNPs in vivo and in vitro. Relying on a world-class experimental validation platform, it empowers the development of multi-organ targeted nanomaterials, achieving the successful implementation of AI + nanomaterial applications.

Attachment2024 "Emerging 100" List